Windlas Biotech Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ykyic2s3a00q389ho0evjvet.pdf

Key Takeaways


Injectable Ramp-Up: Behind Schedule, Central to the Story

Hitesh Windlass: "The reason we did injectables is because a lot of the available injectable plants from an inorganic perspective are very, very old infrastructure. They're not even meeting the GMP requirements that have come in new Schedule M and even looking further."

Inorganic Strategy: Active Search, Premium Tolerated

Komal Gupta: "We are very much open and very actively looking at various opportunities and would be open to acquire an asset even at a premium if we see good synergy with our business and potential where we don't have to do the fixing of a very critical problem."

Trade Generics & CDMO: Structural Tailwinds, Market Share Play


Exports: Early-Stage Build-Out


ESOPs & People: Investment Framed as Strategic Necessity

Hitesh Windlass: "If you look at how much we have invested in capex since we came to public market, we have an injectable plant. We added a Plant-2 extension. We are now going for Plant-6. We are talking about doing inorganic. So this, if you don't do, then the strategy remains half baked."

Margins: Investment Phase, No Roadmap Offered


Guidance & Commitments

CommitmentSpecificsTimeline
Plant-6 commissioningFacility to be commissionedWithin FY26
New dosage form additionAdd one dosage form organically if no inorganic deal foundWhen injectables near peak capacity utilization
Export dossier filingsInjectable product dossiers under preparation, will be filedNot specified
Inventory days normalizationInventory days should return to normal levels after GST-driven drop to 29 daysNot specified

Key Metrics

MetricQ2 FY26
Revenue from operations₹222 cr, +19% YoY
H1 FY26 revenue from operations₹432 cr, +19% YoY
EBITDA₹29 cr
EBITDA margin (excl. ESOP impact)13.5%
PAT₹18 cr
H1 FY26 PAT₹35 cr
Gross margin improvement68 bps YoY
H1 FY26 EPS₹16.91, +21% YoY
Generic Formulations CDMO growth18% YoY (Q2 and H1 FY26)
Trade Generics & Institutional growth24% YoY in Q2 FY26, 25% in H1 FY26
Exports growth13% YoY in Q2 FY26, 23% in H1 FY26
Indian pharma market growth7.7% YoY, volume decline of 0.2%
ESOP non-cash expenditure₹1.2 cr in Q2 FY26
Inventory days29 days, down from 39 days due to GST caution
Revenue from India94% of total revenues